John Marotta bought $502K of Azenta (AZTA)
Executed Nov 18 2024, disclosed Nov 19 2024, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Nov 19 2024), the stock returned +24.2% (delay-adjusted); from the execution session (Nov 18 2024), +11.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
John Marotta (President and CEO) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Azenta, Inc. (AZTA). Across 1 priced purchase filing, the average 21-session return was +11.6% from execution and +24.2% from disclosure (delay-adjusted; derived). The largest single filing was $502K of AZTA (12,717 sh × $39.48, as filed), executed Nov 18 2024.
Healthcare · Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the Un…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→